| Product Name | BMP6 antibody [74219.11] |
|---|---|
| Antibody Type | Primary Antibodies |
| Product description | Mouse monoclonal [74219.11] to BMP6Bone Morphogenetic Proteins (BMP) are members of the TGF beta superfamily of cytokines that affect bone and cartilage formation. Similar to other TGF beta family proteins, BMPs are highly conserved across animal species.BMPs are involved in embryogenesis and morphogenesis of various tissues and organs. BMP6 is an autocrine stimulator of chondrocyte differentiation and has been implicated in the development of embryonic kidney and urinary systems. It is involved in liver growth and differentiation, keratinocyte differentiation, and regulation of neuronal tissue development. BMP6 expression is localized to muscle cells in the developing human fetal intestine, expanding its role as a regulator of developing tissues. |
| Immunogen | Recombinant full length protein (Human) expressed in CHO cells. |
| Clonality | Monoclonal |
|---|---|
| Isotype | IgG2 |
| Clone Number | 74219.11 |
| Host Species | Mouse |
| Tested Applications | ELISANeutWB |
| ELISA: Use at a concentration of 0.5 - 1.0 μg/ml. The detecton limit for recombinant human BMP-6 is approximately 6.2 ng/well. Inhib: Use at a concentration of 1 - 3 μg/ml. WB: Use at a concentration of 1 - 20 μg/ml. The detection limit for recombinant human BMP6 is approximately 20 ng/lane under non-reducing conditions. Anti-Human Bone Morphogenetic Protein 6 (BMP6) is measured by its ability to neutralize the bioactivity of BMP6 in osteoblast MC3T3-E1 cells. Recombinant human BMP6 is added to various concentrations of the antibody for 1 hour at 37 °C in a 96 well microplate. Following this pre-incubation, MC3T3-E1 cells are added to the mixture. The assay mixture in a total volume of 100 μl, containing antibody at concentrations of 0.01 μg/ml to 50 μg/ml, recombinant human BMP6 at 750 ng/ml, L-ascorbic acid at 50 μg/ml, and cells at 5 x 10^4 cells/ml, is incubated at 37 °C for 4 days in a humidified CO2 incubator. At the end of the incubation, alkaline phosphatase activity in cell lysate is measured. The Neutralization Dose50 (ND50) for anti-human BMP6 is approximately 1 to 3 μg/ml in the presence of 750 ng/ml of recombinant human BMP6, using the MC3T3-E1 cell line. The ND50 is the concentration of antibody required to yield one-half maximal inhibition of the cytokine activity on a responsive cell line, when the cytokine is present at a concentration just high enough to elicit a maximum response. The exact concentration of antibody required to neutralize human BMP6 activity is dependent on the cytokine concentration, cell type, growth conditions, and the type of activity studied. Optimal dilutions/concentrations should be determined by the end user. | |
| Species Reactivity | Human |
| Concentration | 0.5mg/ml |
| Purification | Protein G |
| Gene Synonyms | 112266, VGR1, 654, BMP6, VGR, P22004 |
|---|---|
| Target | BMP6 |
| Tissue Specificity | This antibody shows less than 5 % cross-reactivity with recombinant human BMP5 and BMP7 and no crossreactivity with recombinant human BMP2 and BMP4 under reducing conditions. |
| Cellular Localization | Secreted |
| Application Notes | ELISA: Use at a concentration of 0.5 - 1.0 μg/ml. The detecton limit for recombinant human BMP-6 is approximately 6.2 ng/well. Inhib: Use at a concentration of 1 - 3 μg/ml. WB: Use at a concentration of 1 - 20 μg/ml. The detection limit for recombinant human BMP6 is approximately 20 ng/lane under non-reducing conditions. Anti-Human Bone Morphogenetic Protein 6 (BMP6) is measured by its ability to neutralize the bioactivity of BMP6 in osteoblast MC3T3-E1 cells. Recombinant human BMP6 is added to various concentrations of the antibody for 1 hour at 37 °C in a 96 well microplate. Following this pre-incubation, MC3T3-E1 cells are added to the mixture. The assay mixture in a total volume of 100 μl, containing antibody at concentrations of 0.01 μg/ml to 50 μg/ml, recombinant human BMP6 at 750 ng/ml, L-ascorbic acid at 50 μg/ml, and cells at 5 x 10^4 cells/ml, is incubated at 37 °C for 4 days in a humidified CO2 incubator. At the end of the incubation, alkaline phosphatase activity in cell lysate is measured. The Neutralization Dose50 (ND50) for anti-human BMP6 is approximately 1 to 3 μg/ml in the presence of 750 ng/ml of recombinant human BMP6, using the MC3T3-E1 cell line. The ND50 is the concentration of antibody required to yield one-half maximal inhibition of the cytokine activity on a responsive cell line, when the cytokine is present at a concentration just high enough to elicit a maximum response. The exact concentration of antibody required to neutralize human BMP6 activity is dependent on the cytokine concentration, cell type, growth conditions, and the type of activity studied. Optimal dilutions/concentrations should be determined by the end user. |
|---|
| Form | Liquid |
|---|---|
| Storage Instructions | Store at 4°C short term. For long-term storage aliquot and store at -20°C long-term. Avoid freeze-thaw cycles. |
| Storage Buffer | Preservative: None Constituents: PBS |
